Is Discovery Research a Luxury or a Necessity in Biotech?-Austin Gurney, PhD-05/10/2016 – 6:00pm

View
Event Information

Event Topic:
Is Discovery Research a Luxury or a Necessity in Biotech?-Austin Gurney, PhD-05/10/2016 – 6:00pm

Date/Time:
Date(s) - 10/05/16
12:00 am

Event Location:
Sunnyvale City Council Chambers- 456 West Olive Ave., Sunnyvale,

Speaker Information

Event Speaker:
Austin Gurney, PhD

Event Speaker Title:
CSO, Senior VP, Molecular and Cellular Biology

Event Speaker Company:
Oncomed Pharmaceuticals

Event Speaker Bio:

Austin Gurney joined OncoMed Pharmaceuticals at its founding as Vice President of Molecular and Cellular Biology. Prior to OncoMed, Dr. Gurney worked at Genentech where his research contributed to the discovery of numerous growth factors and cytokines. He has authored or co-authored more than 60 papers and is listed as an inventor on over 600 patents related to therapeutic applications in immunology and cancer. Dr. Gurney has two decades of experience in biotechnology and in the development of novel therapeutics. Dr. Gurney conducted his PhD work at Case Western Reserve University. He completed post doctoral studies with Dr. Bryan Williams at the Cleveland Clinic, and at Genentech with Dr. David Goeddel. E

Event Details

Cost:
$6 - Students/In-transition - Members only
$11 - Early-bird Registration - Members only
$20 - Late Registration and Non-Members
$25 - Walk-ins

Event Details:
Building a biotech company is challenging for a multitude of reasons. Among the greatest challenges is the difficulty financing a company though the long journey towards the creation of new medicine. Research, particularly basic discovery research is often perceived as a cost and burden which needs to minimized in order to marshal resources towards the advancement of a lead clinical program. However, it can be argued that creating “the next Genentech” will remain metaphor rather than reality without investment in research by new biotechs. The speaker will share his experiences and observations building a biotech anchored on a model of ongoing and substantial investment in basic discovery research. Among their surprising observations: rather than being a cost, research has funded the company!

Leave a Reply

Your email address will not be published. Required fields are marked *